Pharma Nostra

pharmanostra.com.br

A Pharma Nostra® é uma empresa científica, voltada para a pesquisa e desenvolvimento, que tem como carro-chefe a inovação, qualidade e comprometimento com o setor magistral. Durante a sua trajetória, a Pharma Nostra® consolidou-se como especialista no tratamento individualizado, isso porque a marca compreende cada ser humano como único e, com base em suas necessidades específicas, permite tornar qualquer fórmula sob medida e multidisciplinar.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

IN THE WORLD OF BIG PHARMA, AN ITALIAN ORAL SPRAY SURVIVES

Dr ZinX | July 10, 2020

news image

Yonah S. Tehrani, MD on the potential benefit of the Dr ZinX Zinc + Hinokitiol combination: "The antiviral effects and benefits of Zinc and Hinokitiol may have a tremendous impact on affected individuals and health care systems worldwide." Zinc is a mineral of critical importance to the proper functioning of the immune system in all age groups. Zinc deficiency may result in low resistance to viruses and bacteria. Studies dating back to 1974 have shown that zinc supplemen...

Read More

Pharma Tech

THERORNA COMPLETES SERIES A FINANCING TO ACCELERATE PIPELINE DEVELOPMENT AND CLINICAL TRANSFORMATION OF CIRCRNA-BASED PLATFORM

Therorna Inc. | June 21, 2022

news image

Therorna Inc., a China-based biotech company specialized in the development of cutting-edge circular RNA technology-based new vaccines and therapies, announced the completion of a US$42 million Series A financing round. The round was co-led by a well-known industrial investment firm and MSA Capital, with participation from Sherpa Healthcare Partners, 3H Health Investment, and existing investors Quan Capital and Cenova Capital, demonstrating their continuous commitment to supporting Therorna'...

Read More

Business Insights, PHARMACY MARKET

CYTEL AND GSK ADVANCE CLINICAL TRIAL DESIGN WITH SOLARA

Cytel | February 09, 2023

news image

On February 7, 2023, Cytel Inc., a provider of statistical software and advanced analytics in the life sciences industry, announced that GSK, one of the world's top biopharmaceutical firms, signed a three-year strategic agreement to increase GSK’s deployment of the clinical strategy platform Solara (R). This agreement will contribute significantly to the future development of the Solara platform. The platform can help GSK effectively align on trial goals, traverse trial uncertain...

Read More

MAYNE PHARMA ANNOUNCES FDA FILING ACCEPTANCE OF NEW DRUG APPLICATION FOR E4/DRSP IN THE US

Mayne Pharma, Mithra | June 24, 2020

news image

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the New Drug Application (NDA) for E4/DRSP to prevent pregnancy has been accepted for review by the US Food and Drug Administration (FDA). The FDA is expected to complete its review in the first half of calendar 2021. Developed by Mithra Pharmaceuticals SA (Mithra), E4/DRSP is a novel combined oral contraceptive pill containing 15 mg estetrol (E4) and 3 mg drospirenone (DRSP). E4 is a naturally occurring estrogen that is...

Read More
news image

IN THE WORLD OF BIG PHARMA, AN ITALIAN ORAL SPRAY SURVIVES

Dr ZinX | July 10, 2020

Yonah S. Tehrani, MD on the potential benefit of the Dr ZinX Zinc + Hinokitiol combination: "The antiviral effects and benefits of Zinc and Hinokitiol may have a tremendous impact on affected individuals and health care systems worldwide." Zinc is a mineral of critical importance to the proper functioning of the immune system in all age groups. Zinc deficiency may result in low resistance to viruses and bacteria. Studies dating back to 1974 have shown that zinc supplemen...

Read More
news image

Pharma Tech

THERORNA COMPLETES SERIES A FINANCING TO ACCELERATE PIPELINE DEVELOPMENT AND CLINICAL TRANSFORMATION OF CIRCRNA-BASED PLATFORM

Therorna Inc. | June 21, 2022

Therorna Inc., a China-based biotech company specialized in the development of cutting-edge circular RNA technology-based new vaccines and therapies, announced the completion of a US$42 million Series A financing round. The round was co-led by a well-known industrial investment firm and MSA Capital, with participation from Sherpa Healthcare Partners, 3H Health Investment, and existing investors Quan Capital and Cenova Capital, demonstrating their continuous commitment to supporting Therorna'...

Read More
news image

Business Insights, PHARMACY MARKET

CYTEL AND GSK ADVANCE CLINICAL TRIAL DESIGN WITH SOLARA

Cytel | February 09, 2023

On February 7, 2023, Cytel Inc., a provider of statistical software and advanced analytics in the life sciences industry, announced that GSK, one of the world's top biopharmaceutical firms, signed a three-year strategic agreement to increase GSK’s deployment of the clinical strategy platform Solara (R). This agreement will contribute significantly to the future development of the Solara platform. The platform can help GSK effectively align on trial goals, traverse trial uncertain...

Read More
news image

MAYNE PHARMA ANNOUNCES FDA FILING ACCEPTANCE OF NEW DRUG APPLICATION FOR E4/DRSP IN THE US

Mayne Pharma, Mithra | June 24, 2020

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the New Drug Application (NDA) for E4/DRSP to prevent pregnancy has been accepted for review by the US Food and Drug Administration (FDA). The FDA is expected to complete its review in the first half of calendar 2021. Developed by Mithra Pharmaceuticals SA (Mithra), E4/DRSP is a novel combined oral contraceptive pill containing 15 mg estetrol (E4) and 3 mg drospirenone (DRSP). E4 is a naturally occurring estrogen that is...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us